A5034103357- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- Economic and Financial Impacts of Cancer
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- Renal and related cancers
- Colorectal Cancer Treatments and Studies
- Health Systems, Economic Evaluations, Quality of Life
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Hormonal and reproductive studies
- Radiomics and Machine Learning in Medical Imaging
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
Huntsman Cancer Institute
2019-2025
University of Utah
2019-2025
Montefiore Medical Center
2012-2024
Huntsman (United States)
2024
University of Utah Health Care
2022
Albert Einstein College of Medicine
2009-2020
University of Iowa Hospitals and Clinics
2015-2019
University of Iowa
2018-2019
European Society for Blood and Marrow Transplantation
2019
St. Barnabas Hospital
2013-2014
To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy.A multidisciplinary panel medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology, hematology, emergency medicine, nursing, trialists, advocacy experts was convened to update guideline. Guideline development involved a systematic literature review an...
Management of metastatic prostate cancer has undergone a revolution over the past decade with introduction several novel agents and repurposing others. Several clinical trials reported improved outcomes intensification androgen deprivation therapy by addition docetaxel chemotherapy or hormonal (abiraterone, enzalutamide, apalutamide) in castration-sensitive state. Relugolix been recently approved as first oral gonadotropin-releasing hormone receptor antagonist agent superior cardiovascular...
Accurate and efficient triage is crucial for prioritizing care managing resources in emergency rooms. This study investigates the effectiveness of ChatGPT, an advanced artificial intelligence system, assisting health providers with decision-making patients presenting metastatic prostate cancer, focusing on potential to improve both patient outcomes resource allocation.
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following guideline development process as outlined in Methodology Manual . follow Conflict Interest Policy Clinical Practice other guidance (“Guidance”) provided by is not a or definitive guide to treatment options. It intended voluntary use providers should be used conjunction independent professional judgment. Guidance may applicable all patients,...
664 Background: EV-302 /KEYNOTE-A39 (NCT04223856) demonstrated significant progression-free survival (PFS) and overall (OS) benefit with first-line (1L) EV+P vs chemo in patients (pts) la/mUC. is the standard of care (SOC) global treatment guidelines for pts untreated We present 12 mo additional follow-up (>2 y median follow-up) an exploratory analysis confirmed complete response (cCR). Methods: Pts previously la/mUC were randomized 1:1 to receive EV (1.25 mg/kg; Days 1 8; IV) P (200 mg;...
95 Background: Most pts with prostate cancer bone metastasis experience symptomatic skeletal events (SSEs) [PMID: 23884473], leading to increased morbidity and mortality. BMAs have been approved since 2007 are recommended in mCRPC prevent SSEs metastases or a high risk of osteoporotic fracture. Herein, we sought assess the real-world trends BMA administration mCRPC. Methods: We used de-identified nationwide Flatiron Health electronic health record (EHR)-derived database extract pt-level...
Intensification of androgen deprivation therapy (ADT) with either docetaxel or receptor axis-targeted therapies (ARAT) are the current standard care for patients metastatic castration-sensitive prostate cancer (mCSPC). However, biomarkers guiding treatment selection lacking. We hypothesized that ADT intensification ARAT, but not docetaxel, would be associated improved outcomes in de novo (dn)-mCSPC harboring SPOP mutations.Patient-level data from a deidentified nationwide (U.S.-based)...
Importance The treatment paradigm for advanced urothelial carcinoma (aUC) has undergone substantial transformation due to the introduction of effective, novel therapeutic agents. However, outcomes remain poor, and little is known about current approaches attrition rates patients with aUC. Objectives To delineate evolving patterns in aUC using a US-based patient-level sample. Design, Setting, Participants This retrospective cohort study used data from nationwide deidentified electronic health...
Importance Targeted therapies based on underlying tumor genomic susceptible alterations have been approved for patients with metastatic prostate cancer (mPC) and advanced urothelial carcinoma (aUC). Objective To assess trends disparities in next-generation sequencing (NGS) testing among mPC aUC. Design, Setting, Participants This retrospective cohort study used an electronic health record–derived database to extract deidentified data of receiving care from US physician practices,...
The treatment landscape of metastatic prostate cancer (mPCa) is rapidly evolving with the recent approvals poly-ADP ribose polymerase inhibitors (PARPis) as monotherapy or part combination therapy androgen receptor pathway in patients castration-resistant (mCRPC). Already therapeutic armamentarium different types advanced cancers, these molecules have shaped a new era mPCa by targeting genomic pathways altered patients, leading to promising responses. These agents act inhibiting (PARP)...
Background Muscle-invasive urothelial cancer (UC) has a high risk of recurrence after definitive treatment. Nivolumab adjuvant to radical surgery improves disease-free survival in patients with UC recurrence; however, its role chemoradiation therapy (CRT) is unknown. Methods The NEXT trial single-arm, phase-2 study evaluating the efficacy and tolerability nivolumab CRT localized or locoregional UC. primary endpoint failure-free (FFS) at 2 years. Secondary endpoints include patterns...